MORINAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H14N4O2
Molecular Weight	222.2438
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(NCN1CCOCC1)C2=NC=CN=C2

InChI

InChIKey=GVTLAVKAVSKBKK-UHFFFAOYSA-N

InChI=1S/C10H14N4O2/c15-10(9-7-11-1-2-12-9)13-8-14-3-5-16-6-4-14/h1-2,7H,3-6,8H2,(H,13,15)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4953657 | https://www.ncbi.nlm.nih.gov/pubmed/9007735 | http://en.pharmacodia.com/web/drug/1_11056.html | https://www.ncbi.nlm.nih.gov/pubmed/10864178

Morinamide is a second line anti-tuberculous agent. In vitro morinamide demonstrated clear dose-dependent bacteriostatic and bactericidal activities. The anti-mycobacterial effect of morinamide was the same as pyrazinamide and was dependent on the acidity of medium (pH 5.6). Liver function test abnormalities following morinamide therapy are usually mild, and onset of jaundice is extremely uncommon. It has been given orally as the hydrochloride in the treatment of tuberculosis.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tuberculosis 83 Sources: http://en.pharmacodia.com/web/drug/1_11056.html https://www.ncbi.nlm.nih.gov/pubmed/5322284 https://www.ncbi.nlm.nih.gov/pubmed/5322283	Curative		Approved 8429	Piazofolina Approved Use Unknown Launch Date 1991

PubMed

Title	Date	PubMed
[Behavior of some hematochemical data and of the most important biological indexes of disease and of phase in subjects affected by pulmonary tuberculosis treated with morphazinamide].	1965 Sep 1	5322265
[Morphazinamide in the treatment of urinary tuberculosis].	1965 Sep 1	5322266
[On therapeutic effects of morphazinamide, used alone and in association, in recent and chronic pulmonary tuberculosis].	1965 Sep 5	5322267
[Clinical findings on curative action of morphazinamide, administered intravenously, to patients with pulmonary tuberculosis].	1965 Sep 5	5322268
[Clinical experiences with morphazinamide administered in slow venous perfusion in the treatment of pulmonary tuberculosis].	1965 Sep 5	5322269
[Intravenous morphazinamide. Tolerance of the drug and therapeutic effects].	1965 Sep 5	5322270
[Morphazinamide in antitubercular therapy. 2 years of clinical experimentation].	1965 Sep 5	5322272
[Clinical experience with morphazinamide].	1965 Sep 5	5322273
[Clinical research on the use of morphazinamide in pulmonary tuberculosis].	1965 Sep 5	5322274
[Morphazinamide by venous perfusion in therapy of pulmonary tuberculosis].	1965 Sep 5	5322275
[Clinical observations on morphazinamide administered by intravenous perfusion in therapy of pulmonary tuberculosis].	1965 Sep 5	5322276
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method.	2004 Jan	14645324

Patents

Sample Use Guides

In Vivo Use Guide

Mice: 500 mg/kg every day for a period of 20 weeks.

Route of Administration: Other

In Vitro Use Guide

Monocytes separated from human blood were incubated in plastic plates for seven days to mature into macrophage monolayers. After activation with TNF-alpha or IFN-gamma or without prior treatment, the macrophages were infected with M. tuberculosis. Morinamide exhibited a very clear dose-dependent bacteriostatic and bactericidal effect in experiments with ‘normal’ macrophages at concentrations 64, 128 and 256 ug/ml.

Name

Type

Language

MORINAMIDE

Official Name

English

Morinamide [WHO-DD]

Common Name

English

morinamide [INN]

Common Name

English

MORINAMIDE [MART.]

Common Name

English

MORPHAZINAMIDE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ04AK04